This site is no longer maintained and is presented for archive purposes only
| Title: Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. | ||||
| Title Abreviation: Dig Dis Sci | Date of Pub: 1991 Apr | |||
| Author: Afdhal NH; Long A; Lennon J; Crowe J; O'Donoghue DP; | ||||
| Issue/Part/Supplement: 4 | Volume Issue: 36 | Pagination: 449-53 | ||
| MESH Headings: Adult; Clofazimine (AE/*TU); Crohn Disease (*DT); Double-Blind Method; Drug Evaluation; Female; Human; Male; Middle Age; Recurrence; Remission Induction; -RN-; | ||||
| Journal Title Code: EAD | Publication Type: CLINICAL TRIAL | |||
| Date of Entry: 910502N | Entry Month: 9107 | |||
| Country: UNITED STATES | Index Priority: 1 | |||
| Language: Eng | Unique Identifier: 91176827 | |||
| Unique Identifier: 91176827 | ISSN: 0163-2116 | |||
| Abstract: In order to study the effect of clofazimine, a powerful antimycobacterial and antiinflammatory agent, 49 patients with active Crohn's disease were randomized to either corticosteroids plus clofazimine 100 mg daily (N = 25) or to steroids and matching placebo (N = 24). A total of 28 patients (58%) went into disease remission (clofazimine 16, placebo 12; P = NS) with a fall in disease activity score from 10.5 +/- 4.4 to 3.3 +/- 3.5. Patients were treated for a further eight months with clofazimine or placebo and 18 of 28 maintained their remission and completed the study (clofazimine 12, placebo 6; P = NS). Side effects were minor and consisted of skin rash and increased pigmentation. Clofazimine as a solitary antimycobacterial agent appears ineffective in inducing remission in Crohn's disease but may have a role in either disease maintenance or combination chemotherapy. | ||||
| Abstract By: Author | ||||
| Address: Department of Gastroenterology, St. Vincents Hospital, Dublin, Ireland. | ||||